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FK 506 is a powerful new investigational immunosup-
. pressant that has been used successfully first as an 
organ rescue agent and then as a primary antirejection 
agent. FK 506 has been shown to have a favorable profile 
on pancreatic islets in vitro'; however, the agent does 
decrease glucose-induced insulin release at high concen-
trations from bo~ rodent2•3 and human islets.2 This agent 
also prolongs the clearance of glucose and decreases 
insulin release from transplanted dog islets in vivo.4 and is 
diabetogenic in some species of animalss and more impor-
tantly in adult humans.6 The aim of this study was to 
the magnitude of the diabetogenic effect of FK 
506 in pediatric patients undergoing organ transplantation. 
METHODS 
Patients who developed insulin-requiring diabetes were identified 
using a variety of methods including outpatient chart reviews. 
review of endocrine consults for diabetes management. informa-
tion from transplant physicians and nurse coordinators. and 
contact with referring physicians to identify problems that oc-
curred after hospital discharge. 
RESULTS 
From September 1989 to May 1991206 children received 
FK 506 for the following indications: 108 primary liver 
transplants, 44liver "rescues." 1 liver/kidney transplant. 3 
liver/small bowel transplants. 22 primary kidneys, 9 kidney 
"rescues." 16 primary hearts. and 3 heart "rescues." 
Patients who had diabetes mellitus prior to the transplant 
and patients who underwent upper abdominal exenteration 
including pancreatectomy and pancreatic islet transplanta-
tion were excluded from the analysis. Only three pediatric 
patients developed insulin-requiring diabetes while on FK 
506 as a single agent. AU patients had been off steroids at 
least 1 week at the time that diabetes developed. 
The three patients who developed diabetes were adoles-
cents with liver disease who were switched to FK 506 in an 
attempt to rescue a previously transplanted liver with 
chronic rejection despite maximal standard immunosup-
pressive drugs. All patients were treated with cyclosporine 
(CyA) and steroids prior to the switch. CyA was stopped 
and FK 506 treatment was immediately instituted. Rejec-
tion was successfully managed in all patients initially; 
however. one patient required retransplantation for recur-
rence of autoimmune hepatitis 17 months after the switch 
(Table 1). Only one patient had a high plasma FK level at 
any time prior to developing diabetes (15 nglmL, patient 3. 
Table 1). All patients have returned to full activities. 
Diabetes in the setting of organ rescue developed late 
(from 17 to 27 days). All patients were symptomatic from 
hyperglycemia and plasma glucose levels ranged from 326 
mgldL to > 1.000 mgldL. No patient had ketonuria. Only 
one patient was obese and this pat,ent had evidence of mild 
acanthosis nigricans (a skin mlPlifestation of insulin resis-
tance) on the neck (patient 3). Two of the three patients 
had a positive faniily history of type 11 diabetes mellitus. 
After an overnight fast; the morning insulin was held and 
plasma C-peptide levels were drawn. C-peptide levels. 
which reflect endogenous insulin production. were ele-
vated in all three patients compared with normal controls. 
Two of the three patients have been able to discontinue the 
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Table 1. ChU~ of Pedlelrlc P8tIenta Who Denlaped IDo. During SwItch to FK 508 
Family IniIIII 
Hillary LiwIr Tlmeto Glucae C.f'epIIde CumIIII 
PaIIInt AgelS8x l~ DIabIIII 0'- DIabIIII ~dF (mgfdL.) I<MaIa HLA (StaIuI) CunInI Status HbA1C(%) 
131M No Type II CAH 17 367 Negative Dr3 Present 011 Insulin at 9 rno; 4.0 
retransplant 17 
rna for recurrent 
autoimmune 
hepatitis 
2 13/F No None Cryplo 27 1.079 Negative Dr4 Present 011 insulin at 7 mo 5.4 
cirrhosis 
3 121M Yes Type II Cryplo 21 326 Negative Dr4 P .... On insulin at 11 9.0 
cirrho8ia mo 
AbbnMation: 100M. Insulin - dependent diabelllll!llliIUI; CAH. autaUnmune cIvonic acIIve hepetiIIs: HbA1c. GIycoIyI8ted hemoglobin ~nf: 3.9% to 5.9%) • 
.. 
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use of exogenous insulin and maintain normoglycemia and 
a normal glycosylated hemoglobin but one patient still 
requires twice daily insulin injections up to II months after 
the switch. 
DISCUSSION 
The immunosuppressive agent FK 506 is a powerful new 
drug in the armamentarium used to control rejection of 
transplanted organs. A diabetogenic effect of the drug has 
been noted in adults; however. there are no reports of the 
magnitude of this effect in children. 
The frequency of developing new onset insulin-requiring 
diabetes in children treated with FK 506 was low «2%). 
This was somewhat higher in the setting of liver rescue 
(7%). Thus far. no new onset insulin-requiring diabetes has 
been noted in kidney or heart rescue patients. The data 
support the emerging profile of a favorable therapeutic 
margin of this drug especially in the pediatric population. 
Our observation of liver rescue as a setting of increased 
risk to develop diabetes is similar to what has been 
observed previously in adults.7 Also. similarly to what has 
been noted in adults. all three children had evidence of 
glucose intolerance prior to the switch to FK 506 although 
none required insulin treatment while on CyA and ste-
roids. Diabetes in the setting of liver rescue occurs late (2 
weeks to 1 month) and glucose monitoring should be 
performed frequently for several weeks after the switch in 
"rescue" patients. particularly in those with antecedent 
glucose intolerance. family history of diabetes. or obesity. 
Patients on rescue protocols should be taught to recognize 
the symptoms of diabetes and report if these symptoms 
occur after hospital discharge. If the patient develops 
diabetes in this setting. they should receive education 
about increasing testing frequency and insulin adjustments 
for changes in immunosuppression. Insulin may be reo 
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quired for long periods of time but patients may be able to 
suspend the use of exogenous insulin based on results of 
home monitoring and glycosylated hemoglobin values. 
The mechanism of diabetes onset in this setting is unclear. 
It is possible that since FK 506 and Cy A are both lipophilic 
substances and are concentrated in the pancreas.ulocal 
concentrations of both drugs in the pancreas allow for a 
negative synergistic inhibition of insulin release. 
A synergistic immunosuppressive effect of the two 
agents used in combination has previously been report-
ed;lo however. in humans their combined effects have 
been too toxic to allow combination of these two agents. 
The absence of ketonuria and presence of high measure-
able C-peptide levels in our patients suggest a component 
of insulin resistance for which the islets cannot compen-
sate. It will be of interest to study the effects of this drug 
when used as a single agent on insulin secretion and insulin 
action. 
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